Saltar al contenido
PivotalWire
Domingo 22 nov 2026SEC · NASDAQ biomédico

Calendario›BIIB›Omaveloxolone

Omaveloxolone

Ensayo de BIOGEN INC. en Voluntarios sanos.

Todo sobre el fármaco: Omaveloxolone.

Fase
Fase 1
Estado
Completado
Participantes
52
previstos
Centros
1
Fin del objetivo primario
ago 2025
fecha real

Título oficial en el registro (en inglés): A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, abierto. Comenzó en jun 2025.

De principio a fin

  1. Empieza el ensayo (jun 2025)
  2. Lectura de resultados ago 2025 (real)
  3. Hoy

Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.

Qué mide

Maximum Observed Plasma Concentration (Cmax) of Omaveloxolone (Pre-dose and at multiple time points post dose up to Day 29) (del registro, en inglés)

Qué se prueba

Se compara cómo procesa el cuerpo BIIB141 tomado en cápsulas enteras frente a espolvoreado sobre yogur.

Lo que dice el documentoHow does the body process BIIB141 when taken as whole capsules compared to being sprinkled over yogurt? Researchers will also learn more about : * How many participants have adverse reactions during the study.

Traducción automática (claude-haiku-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

Cómo lo describe el promotor

En el documentoEn inglés, del registroIn this study, researchers will learn more about how BIIB141, also known as omaveloxolone or SKYCLARYS®, is processed in the body when taken in different ways. This drug has been approved, or made available for doctors to prescribe, for people with Friedrich's Ataxia (FA) who are at least 16 years old. Currently, people with FA can take it either as whole capsules or opening the capsules and sprinkling its contents over applesauce. The main goal of this study is to learn if BIIB141 is processed any differently when taken sprinkled over low-fat, non-Greek yogurt compared to whole capsules. This will help researchers learn if yogurt could be another option for people to take BIIB141 with. The main questions researchers want to answer in this study are : • How does the body process BIIB141 when taken as whole capsules compared to being sprinkled over yogurt? Researchers will also learn more about : * How many participants have adverse reactions during the study. An adverse reaction is a health problem that may be caused by the study drug. * If there are any changes in the participants' overall health during the study This study will be done as follows: * Participants will be screened to check if they can join the study. The screening period will be up to 28 days, after which participants will check into their study research center. * Participants will stay at the study research center for about 30 days. * This is a "crossover" study. In this kind of study, all participants receive the same 2 or more study drugs (or ways of taking the drug), but the order in which they receive them depends on the group they are randomly assigned to. * In Group 1, participants will take a single dose of BIIB141 as a capsule, followed by a break of 14 days. Then, the participants will take a single dose of BIIB141 sprinkled over yogurt. * In Group 2, participants will take a single dose of BIIB141 sprinkled over yogurt, followed by a break of 14 days. Then, the participants will take a single dose of BIIB141 as a capsule. * Each participant will be in the study for up to 57 days.

Sigue a BIIB y recibe cada mañana en tu correo lo que haya presentado ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Más ensayos de BIIB

EnsayoFaseEstadoLectura de resultados
Diranersen · CELIAFase 2En marcha, sin reclutarmar 2026 (real)
BIIB142Fase 1Reclutando pacientesago 2026 (prevista, ya pasada: sin actualizar en el registro)
Litifilimab · TOPAZ-2Fase 3En marcha, sin reclutarsep 2026 (prevista, ya pasada: sin actualizar en el registro)
Litifilimab · TOPAZ-1Fase 3En marcha, sin reclutarsep 2026 (prevista, ya pasada: sin actualizar en el registro)
Litifilimab · AMETHYSTFase 2/3En marcha, sin reclutaroct 2026 (prevista, ya pasada: sin actualizar en el registro)
Felzartamab · TRANSCENDFase 3En marcha, sin reclutardic 2026 (prevista)

Todos los de BIIB, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07019064), actualizada en sep 2025.